Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Melanoma 11Triple Negative Breast Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Neoplasms 7Head and Neck Neoplasms 7Multiple Myeloma 6Carcinoma, Transitional Cell 6Carcinoma, Renal Cell 6Pancreatic Neoplasms 5Lung Neoplasms 4Recurrence 3Prostatic Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Sarcoma 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Kidney Neoplasms 2Inflammatory Breast Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Urothelial Cancer 1Thyroid Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Spinocerebellar Degenerations 1

Interventions

Doxorubicin 2tazemetostat 1romidepsin 1pembrolizumab 1etoposide phosphate 1duvelisib 1cc-486 1Vincristine 1Prednisone 1Prednisolone 1Melphalan 1Etoposide 1Cytarabine 1Cyclophosphamide 1Carmustine 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Enteropathy-Associated T-Cell Lymphoma × pembrolizumab × Clear all
NCT04795869 2023-10-10

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Northwestern University

Phase 2 Withdrawn
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡